SLC5A2 and kidney failure: Recently, SGLT2 inhibitors are being studied in several randomized clinical trials in peritoneal dialysis patients as a target to reduce the glucose intake in the peritoneal membrane and to improve ultrafiltration but also the cardiometabolic profile26,27.